Psoriasis - Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Psoriasis - Identifying and
Commercializing First-in-Class Innovation
2
Summary
 
GBI Research has released the pharma report
Frontier Pharma Psoriasis - Identifying and
Commercializing First-in-Class Innovation, which
identifies and assesses first-in-class innovation
in the psoriasis development pipeline. Over the
last decade, a greater understanding of the
underlying pathophysiology of psoriasis has
increased emphasis on developing
immuneomodulating therapies, as opposed to
largely symptomatic treatments. This is currently
reflected in a competitive market dominated by
multiple disease-modifying biologic therapies
(inhibitors of TNF-a and IL-12/IL-23) and generic
small-molecule therapies. Despite this, there are
significant unmet needs in the market, including
safety concerns regarding immunomodulation. This
is a particularly important issue for the
long-term commercial and clinical success of
psoriatic therapeutics, especially for emerging
biologics. Another unmet need is ease of drug
application, as biologic drug delivery is
invasive and painful.
3
Summary
This allows for pipeline programs that offer a
more refined approach to immunomodulation and
ease of drug application to gain market share
upon entry. In a pipeline of over 200 programs,
approximately one third exhibits a novel
mechanism of action. Innovative programs target a
wide range of molecules implicated in immune
signaling, such as cytokines and B and T cell
antigens. Several promising first-in-class
therapies can selectively modulate specific
subsets of immune cells without compromising the
entire immune system. In particular, biologics
that target a subset of T cells, which are
strongly implicated in autoimmune
pathophysiology, could allow for specificity of
immune suppression and thereby reduce adverse
side effects. Based on clinical trials,
IL-17-targeted therapies have demonstrated
superiority over currently established therapies
in achieving advanced clinical endpoints. Get
more about this report at http//www.bigmarketres
earch.com/frontier-pharma-psoriasis-identifying-an
d-commercializing-first-in-class-innovation-market

4
Scope

• A brief introduction to psoriasis, including
  symptoms, pathophysiology, and overview of
  pharmacotherapy
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation
• Overview of how innovative products are
  contributing to the pipeline and market for
  psoriasis
• Comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of phase distribution, molecule type, molecular
  target, and administration route
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets
• Assessment of the licensing and co-development
  deals for psoriasis therapies
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/132449
•  

5
Table Of Content
1 Table of Contents 2 The Case for Innovation 7 3
Clinical and Commercial Landscape 9 4 Assessment
of Psoriasis Pipeline and Innovation 27 5
First-in-Class Target and Pipeline Program
Evaluation 40 6 Deals and Strategic
Consolidations 59 7 Appendix 66
6
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/frontier-pharma-p
soriasis-identifying-and-commercializing-first-in-
class-innovation-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
sales_at_bigmarketresearch.com